X-Ray Equipment Markets in Americas to 2020 - Market Size, Development, and Forecasts; New Report Launched

The report package X-Ray Equipment Markets in Americas to 2020 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for X-ray equipment in different American countries. The package includes X-ray equipment country reports from the following countries:

Argentina, Bolivia, Canada, Colombia, Ecuador, Panama, Peru, United States

The research includes historic data from 2009 to 2015 and forecasts until 2020 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

The reports help answer the following questions:

• What is the current size of the X-ray equipment market in different American countries?
• How is the X-ray equipment market divided into different product segments?
• How are the overall market and different product segments growing?
• How is the market predicted to develop in the future?
• What is the market potential compared to other countries?

The latest industry data included in the reports:

• Overall X-ray equipment market size, 2009-2020
• X-ray equipment market size by product segment, 2009-2020
• Growth rates of the overall X-ray equipment market and different product segments, 2009-2020
• Shares of different product segments of the overall X-ray equipment market, 2008, 2014 and 2019
• Market Potential Rates of the overall X-ray equipment market and different product segments

The market data is given for the following product segments:

• Dental X-ray equipment
• Medical X-ray equipment
• Non-medical X-ray equipment
• X-ray tubes

Among the key reasons to purchase include the following:

• Gain an outlook of the historic development, current market situation, and future outlook of the X-ray equipment market in different American countries to 2020
• Track industry developments and identify market opportunities
• Plan and develop marketing, market-entry, market expansion, and other business strategies by identifying the key market opportunities and prospects
• Save time and money with the readily accessible key market data included in the reports. The data is clearly presented and can be easily incorporated into presentations and internal reports.

Spanning over 184 pages, 13 Tables and 11 Graphs “X-Ray Equipment Markets in Americas to 2020 - Market Size, Development, and Forecasts” report covers Market for X-Ray Equipment in the Country in Question, Forecasts and Future Outlook, Market Potential Rates, X-Ray Equipment Market Size Compared to Market Growth in Different Countries, Market Definition, Methodology and Sources.

For more information Visit at: http://mrr.cm/Jzk

Related Reports:

X-Ray Equipment Markets in Asia to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/JzZ

X-Ray Equipment Markets in Western Europe to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/Jz4

X-Ray Equipment Markets in Eastern Europe to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/Jzo

United States Male External Catheters Industry 2016 Market Report; Launched via MarketResearchReports.com

The United States Male External Catheters Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Male External Catheters industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Male External Catheters market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on United States major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Male External Catheters industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 149 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Spanning over 133 pages “United States Male External Catheters Industry 2016 Market Research Report” report covers Industry Overview, Manufacturing Cost Structure Analysis of Male External Catheters, Technical Data and Manufacturing Plants Analysis, Production Analysis of Male External Catheters by Regions, Type, and Applications, Consumption Volume and Consumption Value Analysis of Male External Catheters by Regions, Analysis of Male External Catheters Production, Supply, Sales and Market Status 2011-2016, Analysis of Male External Catheters Industry Key Manufacturers, Price and Gross Margin Analysis, Marketing Trader or Distributor Analysis of Male External Catheters, Development Trend of Male External Catheters Industry 2016-2021, Industry Chain Suppliers of Male External Catheters with Contact Information, New Project Investment Feasibility Analysis of Male External Catheters, Conclusion of the United States Male External Catheters Industry 2016 Market Research Report.

For more information Visit at: http://mrr.cm/JzT

Related Reports:

Global ECG Devices Sales Market Report 2021 - Visit at - http://mrr.cm/Jzp

United States Heart-lung Machines Sales Market Report 2021 - Visit at - http://mrr.cm/JzG

Global Advanced Wound Care Sales Market Report 2021 - Visit at - http://mrr.cm/Jzx

Wheelchair Markets in Asia to 2020 - Market Size, Development, and Forecasts; New Report Launched

The report package Wheelchair Markets in Asia to 2020 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for wheelchairs in different Asian countries. The package includes wheelchair country reports from the following countries:

Bangladesh, China, India, Indonesia, Iran, Japan, Jordan, Kazakhstan, Kyrgyzstan, Lebanon, Malaysia, Mongolia, Nepal, Oman, Pakistan, Philippines, South Korea, Thailand, Vietnam

The research includes historic data from 2009 to 2015 and forecasts until 2020 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

The reports help answer the following questions:

• What is the current size of the wheelchair market in different Asian countries?
• How is the wheelchair market divided into different product segments?
• How are the overall market and different product segments growing?
• How is the market predicted to develop in the future?
• What is the market potential compared to other countries?

The latest industry data included in the reports:

• Overall wheelchair market size, 2009-2020
• Wheelchair market size by product segment, 2009-2020
• Growth rates of the overall wheelchair market and different product segments, 2009-2020
• Shares of different product segments of the overall wheelchair market, 2008, 2014 and 2019
• Market Potential Rates of the overall wheelchair market and different product segments

The market data is given for the following product segments:

• Manual wheelchairs
• Motorized wheelchairs
• Wheelchair parts

Among the key reasons to purchase include the following:

• Gain an outlook of the historic development, current market situation, and future outlook of the wheelchair market in different Asian countries to 2020
• Track industry developments and identify market opportunities
• Plan and develop marketing, market-entry, market expansion, and other business strategies by identifying the key market opportunities and prospects
• Save time and money with the readily accessible key market data included in the reports. The data is clearly presented and can be easily incorporated into presentations and internal reports.

Spanning over 399 pages, 11 Tables and 9 Graphs “Wheelchair Markets in Asia to 2020 - Market Size, Development, and Forecasts” report covers Market for Wheelchairs in the Country in Question, Forecasts and Future Outlook, Market Potential Rates, Wheelchair Market Size Compared to Market Growth in Different Countries, Market Definition, Methodology and Sources.

For more information Visit at: http://mrr.cm/JDy

Related Reports:

Wheelchair Markets in Western Europe to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/JDF

Wheelchair Markets in Americas to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/JDt

Wheelchair Markets in Europe to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/JDv

Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape; New Report Launched

Despite 330 Products in the Pipeline, Stem Cell Therapies Still Face Commercial Challenges

While steady progress in clinical research and increasing evidence of product effectiveness are significant driving factors for growth in the stem cell therapies market, a number of obstacles remain before they become widely commercially viable, according to new research.

The company’s latest report states that the stem cell therapy pipeline as a whole is relatively large, with 330 products in active development across all stages. Indeed, R&D within the sector is gaining momentum as candidates move into clinical development, and the results of clinical studies become apparent, clarifying the therapeutic potential of stem cell therapy.

According to Senior Analyst, states: “The stem cell space provides therapeutic potential in indications where current pharmacological and surgical treatment options are ineffective. However, there remains a significant divide between the number of stem cell therapeutic applications currently available for patients and the number of research programs investigating the wider medical applications of stem-cell-based therapies.

“Stem cells are currently being used for a modest variety of indications, with skin and blood stem cells representing the majority of therapeutic uses. The stem cell industry is pursuing a broad base of therapeutic applications, and this is evident in the R&D efforts observed in the sector, as over 15 therapy areas are being targeted by the stem cell industry in over 1,000 clinical trials.”

Despite promising recent developments within the field of stem cell technology, converting its scientific potential into real therapeutic value still represents a significant challenge.

According to Publisher’s survey of key opinion leaders, the stem cells field is still surrounded by a wide variety of obstacles, most notably the high cost of research, which survey participants stated was the biggest factor limiting stem cell progress.

Senior Analyst concludes: “Manufacturers will need to adopt novel strategies to realize their full potential. It is likely that manufacturing methodologies will use partially or fully automated systems in future approaches, in order to improve yield, purity and cost-effectiveness.

“There have been good strides made by stem cell manufacturing companies, such as those made by Cynata Therapeutics, which is implementing innovative manufacturing methods to generate robust, consistent and inexpensive stem cells. Such companies are pointing towards a promising outlook in this regard.”

Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape report provides an assessment of the current trends in the global stem cell therapy sector, with a particular focus on the technological, competitive, and R&D landscape. It includes a targeted industry survey of experts and key opinion leaders in the stem cell therapies field, as well as extensive secondary research.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

For more information Visit at: http://mrr.cm/JDH

Find all Biotechnology Reports at - http://www.marketresearchreports.com/biotechnology

Medical Furniture Markets in Eastern Europe to 2020 - Market Size, Development, and Forecasts; New Report Launched

The report package Medical Furniture Markets in Eastern Europe to 2020 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for medical furniture in different Eastern European countries. The package includes medical furniture country reports from the following countries:

Armenia, Azerbaijan, Bulgaria, Cyprus, Czech Republic, Estonia, Georgia, Greece, Hungary, Latvia, Lithuania, Macedonia, Moldova, Poland, Romania, Slovakia, Slovenia, Turkey, Ukraine

The research includes historic data from 2009 to 2015 and forecasts until 2020 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

The reports help answer the following questions:

• What is the current size of the medical furniture market in different Eastern European countries?
• How is the medical furniture market divided into different product segments?
• How are the overall market and different product segments growing?
• How is the market predicted to develop in the future?
• What is the market potential compared to other countries?

The latest industry data included in the reports:

• Overall medical furniture market size, 2009-2020
• Medical furniture market size by product segment, 2009-2020
• Growth rates of the overall medical furniture market and different product segments, 2009-2020
• Shares of different product segments of the overall medical furniture market, 2008, 2014 and 2019
• Market Potential Rates of the overall medical furniture market and different product segments

The market data is given for the following product segments:

• Dentists' chairs
• Other medical furniture

Among the key reasons to purchase include the following:

• Gain an outlook of the historic development, current market situation, and future outlook of the medical furniture market in different Eastern European countries to 2020
• Track industry developments and identify market opportunities
• Plan and develop marketing, market-entry, market expansion, and other business strategies by identifying the key market opportunities and prospects
• Save time and money with the readily accessible key market data included in the reports. The data is clearly presented and can be easily incorporated into presentations and internal reports.

Spanning over 361 pages, 9 Tables and 7 Graphs “Medical Furniture Markets in Eastern Europe to 2020 - Market Size, Development, and Forecasts” report covers Market for Medical Furniture in the Country in Question, Forecasts and Future Outlook, Market Potential Rates, Medical Furniture Market Size Compared to Market Growth in Different Countries, Market Definition, Methodology and Sources.

For more information Visit at: http://mrr.cm/JzJ

Related Reports:

Medical Furniture Markets in Europe to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/Jz3

Medical Furniture Markets in Western Europe to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/JzU

Medical Furniture Markets in Asia to 2020 - Market Size, Development, and Forecasts - Visit at - http://mrr.cm/Jzw

Global Hemoperfusion Apparatus Industry 2016 Market Report; Launched via MarketResearchReports.com

In this report, we analyze the Hemoperfusion Apparatus industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2011 to 2016. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2011 to 2016. We also make a prediction of its production and consumption in coming 2016-2021.

At the same time, we classify different Hemoperfusion Apparatus based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What’s more, the Hemoperfusion Apparatus industry development trends and marketing channels are analyzed.

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Spanning over 171 pages “Global Hemoperfusion Apparatus Industry Market Research 2016” report covers Industry Overview of Hemoperfusion Apparatus, Industry Chain Analysis of Hemoperfusion Apparatus, Manufacturing Technology of Hemoperfusion Apparatus, Major Manufacturers Analysis of Hemoperfusion Apparatus, Global Production, Revenue and Price Analysis of Hemoperfusion Apparatus by Regions, Manufacturers, Types and Applications, Global and Major Regions Capacity, Production, Revenue and Growth Rate of Hemoperfusion Apparatus 2011-2016, Consumption Volume, Consumption Value, Import, Export and Sale Price Analysis of Hemoperfusion Apparatus by Regions, Gross and Gross Margin Analysis of Hemoperfusion Apparatus, Marketing Trader or Distributor Analysis of Hemoperfusion Apparatus, Global and Chinese Economic Impact on Hemoperfusion Apparatus Industry, Development Trend Analysis of Hemoperfusion Apparatus, Contact information of Hemoperfusion Apparatus, New Project Investment Feasibility Analysis of Hemoperfusion Apparatus, Conclusion of the Global Hemoperfusion Apparatus Industry 2016 Market Research Report.

For more information Visit at: http://mrr.cm/Jzu

Related Reports;

Global Total Cholesterol Test Kit Industry Market Research 2016 - Visit at - http://mrr.cm/JzL

Global Compute Remote Controlling Enema Taxis Instrument Industry Market Research 2016 - Visit at - http://mrr.cm/Jzb

Global Intramedullary Nails Industry Market Research 2016 - Visit at - http://mrr.cm/JzE

Liver Cancer - Pipeline Review, H1 2016; New Report Launched

Liver Cancer Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery. 

Liver Cancer pipeline therapeutics constitutes close to 313 molecules. Out of which approximately 265 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 18, 63, 48, 4, 113 and 19 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 7, 1, 29 and 3 molecules, respectively.

The report Liver Cancer – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape of Liver Cancer
• The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
• The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Liver Cancer
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For more information Visit at: http://mrr.cm/JDQ

Related Reports;

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDA

Acute Lung Injury - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDd

Burkholderia Infections - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDP

Progressive Supranuclear Palsy - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDW

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016; New Report Launched

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Products under Development by Therapy Area  Number of Products under Development by Therapy Area, H1 2016 

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Global Markets Direct's latest report Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H1 2016, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
• The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
• The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JD4

Related Reports;

Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDo

Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDJ

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JD3

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016; New Report Launched

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity. 

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

The report Histone Deacetylase 2 – Pipeline Review, H1 2016, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
• The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
• The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JDS

Related Reports;

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDT

Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDq

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDc

Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016; New Report Launched

Coagulation Factor XI – Pipeline Review, H1 2016; Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Publisher says; Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

The report 'Coagulation Factor XI – Pipeline Review, H1 2016' outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Scope

• The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
• The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
• The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JDf

Related Reports;

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDY

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDg

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDM

Gamma Secretase (EC 3.4.23.46) - Pipeline Review, H1 2016; New Report Launched

Gamma Secretase – Pipeline Review, H1 2016; Gamma Secretase (EC 3.4.23.46) pipeline Target constitutes close to 25 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Global Markets Direct says; Gamma Secretase (EC 3.4.23.46) Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.

The report 'Gamma Secretase – Pipeline Review, H1 2016' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma Secretase (EC 3.4.23.46) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Scope

• The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.46)
• The report reviews Gamma Secretase (EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Gamma Secretase (EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects
• The report assesses Gamma Secretase (EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.46) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.46)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.46) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JDU

Related Reports;

20s Proteasome - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDw

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDi

P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JD5

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016; New Report Launched

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The report Cathepsin B – Pipeline Review, H1 2016, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by Companies in Phase I, Phase 0, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
• The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JDp

Related Reports;

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDG

Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDN

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JDx